BCL2 and cancer: Because Bcl‐2 family members are central regulators of cell death in malignant tumors (Preuss et al, 2013; Souers et al, 2013; Chan et al, 2015; Faber et al, 2015; Hata et al, 2015; Johnson‐Farley et al, 2015; Elgendy et al, 2016; Karpel‐Massler et al, 2017c), we hypothesized that LXR agonists have an impact on their expression.